18 closest matches · ranked by relevance
Ovarian Neoplasms · Germ Cell Tumors · Immunohistochemistry
Primary: P16 Evaluation in Ovarian Germ Cell Tumors — 7; 4; 0; 6 units on a scale — p=0.001
Teratoma
Primary: Progression Free Survival (PFS) — 71.4; 0.0 Days
Childhood Embryonal Tumor · Childhood Extracranial Germ Cell Tumor · Childhood Extragonadal Germ Cell Tumor
Primary: Event-Free Survival (EFS) — 87.0 Percent probability
Childhood Germ Cell Tumor · Ovarian Cancer · Teratoma
Primary: Overall Survival (OS) — 86; 56 percentage of participants
Brain Tumor · Central Nervous System Tumors · Childhood Germ Cell Tumor
Primary: Response to Induction Chemotherapy — 74; 11 Participants
Extragonadal Germ Cell Tumor · Ovarian Cancer · Testicular Germ Cell Tumor
Primary: Overall Objective Response — 50; 4; 36; 8 participants
Brain and Central Nervous System Tumors · Extragonadal Germ Cell Tumor · Ovarian Cancer
Primary: Rate of Complete Response — 38; 7; 11 Participants
CNS Germ Cell Tumor
Primary: Response Rate — 0; 0; 4; 2 Participants
Testicular Cancer
Primary: Number of Participants With 2-year Event-Free Survival (EFS) — 28; 11 Participants
Extragonadal Germ Cell Tumor · Teratoma · Testicular Germ Cell Tumor
Primary: Progression-free Survival Rate After 1 Course of Treatment — 48; 59 percentage of participants — p=0.05
Recurrent Uterine Corpus Sarcoma · Uterine Carcinosarcoma
Primary: Progression-free Survival (PFS) > 6 Months — 17.8 percentage of participants
Childhood Extracranial Germ Cell Tumor · Childhood Extragonadal Malignant Germ Cell Tumor · Childhood Malignant Ovarian Germ Cell Tumor
Primary: Response Rate as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria — 12; 8 participants
Brain and Central Nervous System Tumors · Extragonadal Germ Cell Tumor · Ovarian Cancer
Primary: Response — 12; 6; 5 participants
Extragonadal Germ Cell Tumor · Ovarian Cancer · Teratoma
Primary: Confirmed Objective Response Rate (Complete and Partial Response) as Measured by RECIST Criteria After 2 Courses of Treatment — 3; 7 participants
Brain and Central Nervous System Tumors · Extragonadal Germ Cell Tumor · Ovarian Cancer
Primary: Progression-free Survival — 11.8 Months
Neoplasms, Germ Cell and Embryonal
Primary: Twelve Month Disease-free Survival Rate — 3.5 percentage of participants
Primary Inoperable Thymoma · Local Recurrent Thymoma
Primary: Percent Change in Tumor Volume From Baseline to EOS — -37.38 percentage of tumor volume
Ovarian Cancer Stage IIIC · Ovarian Cancer Stage IV
Primary: Safety: Number of Participants With Freedom From Device and Procedure-related Major Adverse Events — 18 Participants — p=0.1309